French MedTech startup SafeHeal, a medical machine innovator remodeling colorectal surgical procedure, at present introduced a €10 million extension of its oversubscribed €35 million Sequence C financing spherical.
The extension is led by Asabys Companions by its Sabadell Asabys II fund, which joins a syndicate that features Sofinnova Companions, Photo voltaic Eclipse, Gideon Strategic Companions, Polis, and M&L Healthcare.
“We’re delighted to welcome Asabys Companions because the lead investor on this Sequence C extension,” stated Chris Richardson, President & CEO of SafeHeal. “Their addition strengthens our strategic capabilities in MedTech and demonstrates our rising momentum as we advance towards FDA approval and EU industrial launch. We’re equally grateful for the continued assist from Gideon Strategic Companions and the complete syndicate of world-class buyers.”
Based in 2015, SafeHeal is a medical machine firm growing Colovac, a tool supposed as an alternative choice to diverting ostomy in sufferers present process colorectal surgical procedure.
Colovac is a versatile endoluminal bypass sheath designed to scale back the contact of fecal content material on the anastomotic website following colorectal surgical procedure. The machine is positioned endoluminally and is absolutely reversible.
The machine stays in place for roughly 10 days, till the physique’s pure therapeutic and tissue restore processes are full, after which it’s eliminated throughout an endoscopic process with out the necessity for a second surgical intervention.
This allows sufferers to renew their regular life with out the stigma and problems related to an ostomy process.
As a part of the financing, Josep Ll. Sanfeliu, Managing Associate and co-founder of Asabys, will be part of SafeHeal’s Board of Administrators.
Sanfeliu commented: “Asabys is an bold and fast-growing funding agency dedicated to supporting world-class healthcare innovation throughout Europe and past. We’re proud to affix SafeHeal’s investor syndicate, reflecting our perception in each the excellent group and the transformative influence of Colovac for sufferers dealing with colorectal most cancers surgical procedure.
“We sit up for working intently with SafeHeal’s administration and our fellow buyers to assist convey this vital know-how to sufferers worldwide.”
The brand new capital increase will additional speed up SafeHeal’s pivotal U.S. IDE examine and assist the deliberate industrial launch of Colovac within the EU.
